NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO)

  • STATUS
    Recruiting
  • End date
    Sep 15, 2025
  • participants needed
    121
  • sponsor
    Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Updated on 15 May 2022

Summary

This is an open label, phase I/II clinical trial to evaluate the efficacy and safety of 2 cycles of durvalumab without (Arm A) or with (Arm B) tremelimumab in association with ddMVAC as neoadjuvant therapy in patients with MIUC.

Description

Study Population:

Patients with MIUC fit to receive cisplatin.

Study Design:

The trial is designed as a non-comparative, open-label phase I/II study.

Divided in two phases:

The run In phase (I) and a phase II study. During the run-in phase, a limited number of patients (n=12-18) will be treated with durvalumab + ddMVAC or durvalumab + tremelimumab + ddMVAC (6-9 patients each). If the toxicity rate is acceptable (not higher than 2 out of 6 or 3 out of 9 patients per arm) the study will continue as a randomized phase II study. During phase II, the efficacy and safety of durvalumab + ddMVAC and durvalumab + tremelimumab + ddMVAC

Research hypothesis:

Combination of checkpoint inhibitors (CPI), durvalumab ± tremelimumab, with neoadjuvant ddMVAC will improve the pathological complete response (pCR) rate in patients with muscle-invasive urothelial carcinoma (MIUC). No additional toxicity of the combination CPI + ddMVAC is expected.

Investigational Product(s):

Durvalumab: 1500 mg IV D1 every 28 days Durvalumab will be administered at the hospital every 28 days prior to administration of ddMVAC on D1.

Tremelimumab 75 mg IV D1 every 28 days Tremelimumab will be administered first, with durvalumab infusion starting approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion.

Translational research:

Mechanism of response/resistance to neoadjuvant treatment will be assessed by comparing molecular and immunological tumor profiles before treatment (transurethral resection tumor samples) and after treatment (cystectomy samples). In addition, circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) will be analysed during treatment (ctDNA and utDNA) and after surgery (ctDNA).

Immunological profiles will be established using a specific metagene signature for major cell types of the tumor microenvironment and chemokines, cytokines and regulatory molecules , and will be validated using relevant markers by immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) tumor sections.

Metabolomic profiling will also be conducted by analyzing metabolites present in urinary samples with a Proton-based nuclear magnetic resonance (1H-NMR), and correlations with prognosis, molecular profile or/and with immunological signature determined.

Finally, correlations between tumor pathological factors (e.g., pTNM, nuclear grade, variant squamous differentiation or sarcomatoid dedifferentiation) and prognosis will be evaluated using IHC on FFPE tissue sections.

Sample Size: Approximately 120 patients are planned to be included.

Details
Condition Infiltrating Bladder Urothelial Carcinoma
Treatment tremelimumab, durvalumab, MVAC Protocol
Clinical Study IdentifierNCT03549715
SponsorAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Last Modified on15 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent and any locally required authorization (e.g., EU Data Privacy Directive in the EU) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
Age ≥18 years at time of study entry
Histologically confirmed MIUC (also termed TCC) of the bladder. Patients with mixed histologies are required to have a dominant transitional cell pattern (urothelial carcinoma must be > 50%)
Localized MIUC of the bladder with clinical stage T2-T4a and ≤N1 disease ( the single lymph node must be < 15 mm (short axis) on imaging
Patients with urothelial carcinoma of the prostatic urethra
Bodyweight >45kg
Patients eligible for cisplatin-based neoadjuvant chemotherapy, including
Creatinine clearance (CL) >60 mL/min based on the Modification of Diet in Renal Disease Study (MDRD) formula
Cardiac left ventricular ejection fraction (LVEF) ≥50%
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Absence of metastasis, as confirmed by a negative baseline CT or MRI scan of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization. Patients with clinical stage N1 disease are eligible if the single lymph node measures ≤2 cm in greatest dimension
Adequate organ and marrow function as defined below (obtained within 14 days prior to the first study treatment)
Hemoglobin ≥10.0 g/dL (patients may be transfused to meet this criterion)
Absolute neutrophil count (ANC) ≥1500 cells/μL (without G-CSF support within 2 weeks prior to Cycle 1, Day 1)
WBC counts >2500/µL
Platelet count ≥100,000/µL (without transfusion within 2 weeks prior to Cycle 1, Day 1)
Serum bilirubin ≤1.0 x institutional upper limit of normal (ULN). Patients with known Gilbert disease who have serum bilirubin level ≤3 x ULN may be enrolled
AST, ALT, and alkaline dehydrogenase ≤2.5 x ULN
Partial thromboplastin time/prothrombin time (PTT/PT) ≤1.5 x ULN or international normalized ratio (INR) <1.7 x ULN
Evidence of post-menopausal status or negative urinary or serum pregnancy test for
Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
female pre-menopausal patients. Women will be considered post-menopausal if
they have been amenorrheic for 12 months without an alternative medical cause
The following age-specific requirements apply
Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
Women of childbearing potential and non-sterilized males who are sexually active with
a female partner of childbearing potential must be willing to use
contraceptive methods during the treatment period and for at least 6 months
after the last dose of treatment

Exclusion Criteria

Urothelial carcinoma of the upper tract
Any approved anti-cancer therapy for urothelial carcinoma, including chemotherapy, or immunotherapy prior to initiation of study treatment. Of note, previous intravesical BCG injections are allowed if administered for non-muscle invasive urothelial carcinoma
Primary chemoradiation for bladder preservation for urothelial carcinoma of the bladder
Impaired renal function (glomerular filtration rate [GFR]<60 mL/min); GFR should be assessed by calculation from serum/plasma creatinine (MDRD formula)
Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
Grade 2 or greater hearing loss that contraindicates cisplatin use. Threshold shift of >25 decibel averaged at 2 contiguous test frequencies in least one ear
Grade 2 or greater peripheral neuropathy
Oral anticoagulation treatment (vitamin K antagonist should be replaced by low-molecular-weight heparin)
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug
Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
Major surgical procedure (as defined by the Investigator) other than for diagnosis within 28 days prior to Cycle 1
History of prior organ transplantation, including stem cell allografting
Exception: Patients with Grade 2 hearing loss diagnosed on the audiogram that
are asymptomatic (no complain of hearing loss and no tinnitus) can be enrolled
All micropapillary and plasmacytic forms, with or without squamous cell adenocarcinoma
in the study
Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1
Receipt of therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1
Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina
History of another primary malignancy within 3 years prior to Cycle 1, Day 1, except
for
History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and type I diabetes mellitus on stable dose of insulin may be eligible for this study
Localized low-risk prostate cancer (defined as Stage ≤T2b, Gleason score ≤7, and
prostate-specific antigen [PSA] at prostate cancer diagnosis ≤20 ng/mL [if measured])
treated with curative intent and without PSA recurrence Low-risk prostate cancer
(defined as Stage T1/T2a, Gleason score <7, and PSA ≤10 ng/mL) who are treatment-naive
and undergoing active surveillance Patients with malignancies of a risk of
metastasis/death (e.g., risk of metastasis or death <5% at 5 years) are eligible after
investigator's approval if they meet both of the following criteria: Malignancy
treated with expected curative intent, and no evidence of recurrence or metastasis by
follow-up imaging and any disease-specific tumor markers
History of leptomeningeal carcinomatosis
History of idiopathic pulmonary fibrosis, organizing pneumonia
Serum albumin <25 g/L
LVEF <50%
Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms
calculated from 3 electrocardiograms (ECGs) within 15 minutes at 5 minutes apart
Active infection including tuberculosis (clinical evaluation that includes clinical
history, physical examination and radiographic findings, and TB testing in line with
local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result)
hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients
with a past or resolved HBV infection (defined as the presence of hepatitis B core
antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for
hepatitis C (HCV) antibody are eligible only if PCR is negative for HCV RNA
Current or prior use of immunosuppressive medication within 14 days before the first
dose of durvalumab or tremelimumab. The following are exceptions to this criterion
Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
articular injection) Systemic corticosteroids at physiologic doses not to exceed 10
mg/day of prednisone or its equivalent Steroids as premedication for hypersensitivity
reactions (e.g., CT scan premedication)
Receipt of live attenuated vaccine within 30 days prior to the first dose of study
treatment. Note: Patients, if enrolled, should not receive live vaccine whilst
receiving study treatment and for up to 30 days after the last dose of study treatment
Female patients who are pregnant or breastfeeding, or male or female patients of
reproductive potential who are not willing to employ effective birth control from
screening to 90 days after the last dose of durvalumab monotherapy or 180 days after
the last dose of durvalumab + tremelimumab combination therapy
Known allergy or hypersensitivity to chimeric or humanized antibodies or fusion
proteins, or to any of the study drugs or study drug excipients
Prior randomisation or treatment in a previous durvalumab and/or tremelimumab clinical
study regardless of treatment arm assignment
Any other disease, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that, in the
opinion of the Investigator, makes the patient unsuitable for participation in the
enrollment/randomization code cannot be reused. Withdrawn patients will not be
study Procedures for withdrawal of incorrectly enrolled patients are presented in
replaced
Section 4.3 If a patient withdraws from participation in the study, then his or her
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note